AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 241 min read$UTHR

United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR)

United Therapeutics (UTHR) and Sagimet Biosciences (SGMT) shares declined after Goldman Sachs resumed coverage with Sell ratings. Goldman initiated coverage of UTHR with a Sell rating.

Original reporting
seekingalpha.com
Published Sep 24, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 3:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR · $SGMT
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$UTHRBearishMed
01

Why it matters

The downgrade introduces fresh negative sentiment, likely prompting short‑term selling pressure.

02

Market read

Analyst downgrade for two biotech stocks may trigger short‑term price declines and sector‑wide caution.

03

What to watch

Potential upcoming clinical data or partnership news could offset the downgrade impact.

Relevance 6/10Novelty 6/10Timing: today

Background

Goldman Sachs resumed coverage of multiple biotech firms and issued new Sell ratings.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Goldman Sachs issued a Sell rating on United Therapeutics, causing the stock to fall.

Expected impact

downward

Evidence & confidence

Analyst downgrade is a fresh negative catalyst that typically triggers sell‑offs.

$SGMTBearishMedium confidence
Context

Goldman Sachs issued a Sell rating on Sagimet Biosciences, causing the stock to fall.

Expected impact

downward

Evidence & confidence

Analyst downgrade is a fresh negative catalyst that typically triggers sell‑offs.

Market effects

Sector

Biotech sector may see broader pressure as a major sell rating is applied.

Regional

U.S. biotech stocks could experience slight pullback.

Global

Limited to investors tracking U.S. biotech equities.

Counterpoint

What could challenge this read

Some investors may view the sell rating as an overreaction and look for buying opportunities.

Key entities

  • Analyst
    Goldman Sachs

    Investment bank providing the Sell rating.

Read at source← All news

Related articles

SEP 24
$UTHRHigh

Why United Therapeutics (UTHR) Shares Are Falling Today

United Therapeutics (UTHR) shares fell 4% after Goldman Sachs initiated coverage with a Sell rating, signaling expected underperformance. The stock later recovered slightly to $470.94, down 3.8%. UTHR is down 5.2% YTD and 21.1% from its 52-week high. The company's drug, Tyvaso, showed positive results in a study for lung disease treatment.

financialcontent.com2 min
SEP 24
$UTHRHigh

United Therapeutics Falls as Goldman Sachs Sets $321 Price Target

United Therapeutics' shares dropped after Goldman Sachs gave it a Sell rating and a $321 price target, citing high growth expectations and valuation concerns. The firm sees challenges in commercializing Tyvaso and new therapies. Goldman also downgraded Sagimet Biosciences to Sell with a $7 target, citing commercial hurdles.

citybiz.co1 min
SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min